Who are ropinirole immediate release's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abilify (aripiprazole), Risperidone and Ramelteon, Quetiapine 600mg, A-prexa, risperidone (Risperdal), paliperidone clozapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropinirole-immediate-release.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

ropinirole immediate release — Competitive Intelligence Brief

ropinirole immediate release (ropinirole immediate release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dopamine agonist. Area: Neurology.

phase 3 dopamine agonist D2 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ropinirole immediate release (ropinirole immediate release) — GlaxoSmithKline. Ropinirole is a dopamine agonist that works by activating dopamine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ropinirole immediate release TARGET	ropinirole immediate release	GlaxoSmithKline	phase 3	dopamine agonist	D2 receptor
Abilify (aripiprazole)	Abilify (aripiprazole)	Genovate Biotechnology Co., Ltd.,	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Quetiapine 600mg	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
A-prexa	A-prexa	HK inno.N Corporation	marketed	Atypical antipsychotic	D2 receptor
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (dopamine agonist class)

GlaxoSmithKline · 3 drugs in this class
Gary Archer Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ropinirole immediate release — Competitive Intelligence Brief. https://druglandscape.com/ci/ropinirole-immediate-release. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab